SIRT1 and cardiomyopathy: The data discussed below with SRT1720 treatment allow us to propose that SIRT1 agonists offered during the clinically asymptomatic phase when host has controlled the acute parasitemia but yet not entered the chronic phase of progressive cardiomyopathy, will be most beneficial in arresting the adverse clinical outcomes in Chagas disease.